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Intrinsic caspase-8 activationmediates sensitization of
erlotinib-resistant tumor cells to erlotinib/cell-cycle
inhibitors combination treatment
M Orza´ez*,1,3 , T Guevara1,2,3, M Sancho1 and E Pe´rez-Paya´*,1,2
Inhibitors of the tyrosine kinase activity of epidermal growth factor receptor, as erlotinib, have an established role in treating
several cancer types. However, resistance to erlotinib, particularly in breast cancer cell lines, and erlotinib treatment-associated
disorders have also been described. Also, methods and combination therapies that could reverse resistance and ameliorate non-
desirable effects represent a clinical challenge. Here, we show that the ATP non-competitive CDK2/cyclin A inhibitor NBI1
sensitizes erlotinib-resistant tumor cells to the combination treatment (co-treatment) for apoptosis-mediated cell death.
Furthermore, in erlotinib-sensitive cells, the effective dose of erlotinib was lower in the presence of NBI1. The analysis in the
breast cancer MDA-MB-468 erlotinib-resistant and in lung cancer A549 cell lines of the molecular mechanism underlying the
apoptosis induced by co-treatment highlighted that the accumulation of DNA defects and depletion of cIAP and XIAP activates
the ripoptosome that ultimately activates caspases-8 and -10 and apoptosis. This finding could have significant implications for
future treatment strategies in clinical settings.
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The protein kinase activity of the epidermal growth factor
receptors (EGFRs) is of particular interest in the field of
cancer.1–5 The deregulated proliferation of cancer cells is
sustained by the production of growth factors in conjunction
with the overexpression of growth factor receptors on the cell
membrane. The EGFR family consists of four structurally
related tyrosine kinase (TK) receptors (EGFR/ErbB-1, HER2/
ErbB-2, HER3/ErbB-3 and HER4/ErbB-4) located in the
plasma membrane and activated in response to ligand
binding.6 In physiological conditions, EGFRs are responsible
for the regulation of proliferation, survival, migration and
differentiation.7 Receptor dimerization induces cytoplasmic
TK activity and initiates a cascade of events that produce
survival, antiapoptotic or mitogenic signaling. Indeed, dereg-
ulation of this transduction pathway has a role in the process
of malignant transformation, metastasis and resistance to
apoptosis.8 A number of EGFR inhibitors have been devel-
oped, including monoclonal antibodies that target the ligand-
binding extracellular domain of EGFR (e.g., cetuximab,
panitumumab and trastuzumab) and low-molecular weight
TK inhibitors that compete with adenosine triphosphate (ATP)
to block the catalytic domain of the receptor (e.g., erlotinib,
gefitinib, lapatinib and AG1478).9–11 These therapeutic
agents have an established role in treating non-small cell
lung, colorectal, pancreatic, breast and head and neck
cancers, and erlotinib in particular has been approved by
the FDA.9,12 However, resistance to erlotinib has also been
described, particularly in breast cancer cell lines,13 and FDA
alerts highlighted cases of hepatic failure, gastrointestinal
perforation and ocular disorders14 as a result of erlotinib
treatment. These non-desirable side effects may be amelio-
rated by decreasing the dosage used. Thus, an alternative
might be to design combination therapies that can re-sensitize
erlotinib-resistant cells and synergistically increase the
therapeutic window of the drug, which would be aided by
better understanding its molecular mechanism of action.15–18
The appearance of compensatory mechanisms favoring
survival of cancer cells after therapy represents a limitation in
therapies targeting specific molecules. Molecular pathways
are interconnected, and thus, combination therapy is emer-
ging as an appropriate strategy to treat certain types of
cancer. Two of the strategies being explored are the blockade
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of related and proximal pathways. Accordingly, the dual
inhibition of the vascular endothelial growth factor and EGFR
pathways has been used to overcome the primary and
acquired resistances,19 and combination therapies using
inhibitors of the different members of the EGFRs are being
explored to combat the activation of compensatory survival
mechanisms within the same pathway.20 However, to
effectively inhibit pathways proximal to the principal signaling
pathways used, it is necessary to better understand the
molecular mechanism involved in resistance.
EGFR inhibitors induce changes in the cell cycle, which can
be considered to be proximal to the growth factor receptor
pathway. Cell cycle controls the proliferation of eukaryotic
cells and is controlled by a series of concerted mechanisms
governed by members of the cyclin-dependent kinase family
(CDKs). Increased CDK activity has been reported in cancer
and CDKs have been proposed as targets in the search for
anticancer drugs. Although several, ATP-competitive, syn-
thetic inhibitors of CDKs are currently being developed,21 their
selectivity remains unclear. The high degree of conservation
of the catalytic domain of many protein kinases means ATP
analogs and other ATP-competitive small molecule inhibitors
often act on multiple protein kinases. Moreover, as cellular
ATP levels are in the millimolar range, ATP-competitive
inhibitors must bind with extremely high affinity to the ATP-
binding site in order to be able to out-compete ATP. Indeed,
we have early identified and characterized NBI1 and the cell-
permeant derivative TAT-NBI1 as an all D-amino-acid
hexapeptide, ATP non-competitive inhibitor of the kinase
activity of the CDK/cyclin complexes.22
In sensitive cells, erlotinib inhibits cell growth by increasing
the levels of the endogenous CDK inhibitor p27KIP1, suppres-
sing CDK activity.15,23–25 Then, it was proposed that synthetic
CDK inhibitors would sensitize erlotinib-resistant cells to the
drug. Accordingly, the effects of ATP-competitive CDK
inhibitors like flavopiridol and roscovitine (RC) were analyzed
in combination with EGFR inhibitors,26 although themolecular
mechanisms involved were not described.
Here, we show that NBI1 sensitizes erlotinib-resistant tumor
cells to the combination treatment for apoptosis-mediated cell
death. Importantly, in both erlotinib-sensitive and erlotinib-
resistant cells, the effective dose of erlotinib was lower in the
presence of TAT-NBI1. Among the key hallmarks of this
process are the accumulation of damaged DNA in the cells and
the depletion of cellular levels of inhibitor of apoptosis proteins
(IAP) that induced the activation of caspase-8 and caspase-10.
These two caspases were necessary for full apoptosis
activation. siRNA-based silencing revealed that further activa-
tion of caspase-2 was caspase-10-dependent. Lastly, we
provide novel evidence that TAT-NBI1/erlotinib co-treatment
of erlotinib-resistant cells activates a death domain kinase
RIP1-dependent apoptotic pathway that induces cell death.
Results
Treatment with NBI1 re-sensitizes cancer cell lines to
erlotinib. Previous studies indicated that NBI1 and its cell-
permeant derivative TAT-NBI1 inhibit a series of CDK/cyclin
complexes, producing an anti-proliferative effect mediated by
apoptosis in a number of different cancer cell lines.22 NBI1
interacts in a conserved groove on the surface of some
cyclins and has been proved to inhibit CDK2/cyclin A, CDK1/
cyclin B1, CDK6/cyclin D3 and CDK7/cyclin H with IC50s in
the low micromolar range, whereas the IC50s for the
transcriptional CDK9/cyclin T1 was found 450 mM
(Supplementary Table S1). TAT-NBI1 is able to induce cell
death in a broad panel of cancer cell lines (Supplementary
Figure S1 and Table S2). We have also synthesized a
fluorescent derivative of TAT-NBI1 (CF-TAT-NBI1) and
demonstrated that the drug was internalized by the cell,
reached the nucleus (Supplementary Figure S1A) and
induced cell death by intrinsic, mitochondrial-mediated,
apoptosis as followed by cytochrome c (Cyt c) release to
the cytosol (Supplementary Figure S1B).
It is reasonable to postulate that drug-induced restoration of
CDK inhibition even at sub-lethal NBI1 doses may contribute
to the re-sensitization of resistant cells to EGFR inhibitors,
thereby lowering the effective dose of erlotinib. To test this
hypothesis, we selected three breast cancer cell lines (MCF-7,
SKBr3 andMDA-MB-468) and a non-small cell lung cancer cell
line (A549). These cell lines exhibited a concentration-
dependent sensitivity to erlotinib (Figure 1a). Concentrations
of erlotinib 420mM could not be achieved due to the low
solubility of this compound in culturemedium. Nevertheless, as
the plasma concentration in patients with advance solid tumors
is B5mM at the steady state,27 SKBr3 was considered as
erlotinib-sensitive cell line, whereas the MCF-7, MDA-MB-468
and A549 cell lines were considered erlotinib-resistant
(Figure 1a), in accordance with previously reported data.23
In the present study, we first evaluated the anti-proliferative
activity of TAT-NBI1 in the above-mentioned cell lines to
determine the IC50 values (Figure 1a) and the threshold to
define sublethal concentrations (Supplementary Table S3).
Similar experiments were performed with RC (an ATP-
competitive inhibitor of CDK/cyclin complexes) and erlotinib.
Combination treatments (co-treatments) with TAT-NBI1/
erlotinib and RC/erlotinib were carried out at sublethal
concentrations of each drug and at 72 h of exposure cell
viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) and trypan blue exclu-
sion assays (Figure 1). A complementary, more detailed
kinetic analysis at different exposure times was performed for
MDA-MB-468 and A-549 cell lines (Supplementary Figures
S2A, B and S3A). In the MDA-MB-468 cell line, at 72 h of
exposure, the co-treatments induced the death of almost 75%
of cells (Figures 1b and c). Similar effects were observed in
the A549 (Figures 1f and g) and MCF-7 (Figures 1h and i) cell
lines. Interestingly, TAT-NBI1/erlotinib co-treatment decreased
the lethal concentration (compound concentration needed to
induce 50% of cell death) of erlotinib from 5 to 2 mM in the
SKBr3 erlotinib-sensitive cell line in function of the TAT-NBI1
dose (Figures 1d and e). These results suggested that a co-
administration of a CDK2/cyclin A inhibitor with erlotinib re-
sensitizes resistant cells to erlotinib, and it also reduces the
lethal dose in erlotinib-sensitive cells, thereby widening
the therapeutic window of the drug while diminishing the
possible side effects. The drug combination indices of all
the drug combinations administered were o1, indicating a
synergistic drug behavior.26
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The effect of TAT-NBI1/erlotinib co-treatment on cell-
cycle progression. To initially characterize the in cellulo
mechanism of action of TAT-NBI1/erlotinib co-treatment, we
analyzed the cell-cycle distribution in the cultures at different
time points (24, 48 and 72 h). In the MDA-MB-468, SKBr3
and A549 cell lines (Figures 2a–c, respectively), co-
treatment significantly decreased the proportion of cells in
the G1 and G2/M phases after 48 h, resulting in an increase
in the proportion of subG1 cells after 48 and 72 h of
co-treatment. The proportion of cells accumulated in subG1,
close to 50% in all the three cell lines, was comparable to the
decrease in cell viability observed (Figure 1), suggesting
apoptosis as the main mechanism of cell death. By contrast,
the MCF-7 cell line did not show subG1 population after a
72 h co-treatment (Figure 2d).
Understanding the mechanism of cell death induced by
TAT-NBI1/erlotinib co-treatment. To further explore the
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Cell line HER2 EGFR ER ErlotinibIC50 (M)
NBI1
IC50 (M)
MDA-MB-468 n p n >20 15
SKBr3 p n n 5 10
A549 p p n >20 18
MCF-7 n n p >20 11
MDA-MB-468
SKBr3
A549
MCF-7
Figure 1 TAT-NBI1/erlotinib and roscovitine/erlotinib combination treatments induce cell death. (a) Classification of cell lines as positive (p) or negative (n) for the
expression of the HER2, EGFR and ER receptors. IC50 values of the different cell lines for the treatment with TAT-NBI1 or erlotinib. Cells were treated with sublethal
concentrations of erlotinib (Erl), TAT-NBI1 and roscovitine (RC), or combinations of these drugs. The doses are expressed in mM in the x axes. At 72 h, cell viability was
assessed with MTT and trypan blue exclusion assay. The behavior of the erlotinib-resistant cells MDA-MB-468, A549 and MCF-7 is plotted in panels (b, f, h) and (c, g, i) for
MTT and trypan blue, respectively, while the erlotinib sensitive SKBr3 cells is plotted in panels (d and e). The data are expressed as the mean±S.E. (n43)
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mechanism of TAT-NBI1/erlotinib-induced cytotoxicity, we
analyzed different markers of apoptosis and necrosis. The
exposure of phosphatidylserine residues on the outer leaflet
of the plasma membrane is usually considered a hallmark of
apoptosis.28 Thus, cell staining with fluoresceinisothiocya-
nate-labeled Annexin V, which binds to phosphatidylserine, is
considered to be a marker of early apoptotic events
(AnnVþ ). Propidium iodide (PI) is a DNA intercalating agent
that can be incorporated into cells only after major cell
membrane damages (PIþ ). Hence, the combination of AnnV
and PI cell staining can be used to distinguish apoptotic and
necrotic cell death. Co-treatment of MDA-MB-468 and SKBr3
cell lines produced the typical profile of cells undergoing
apoptosis after 48 h, as both AnnVþ PI (early apoptotic)
and AnnVþ PIþ (late apoptotic) cells could be detected
(Figures 3a and b). Co-treatment of the A549 cell line
resulted in the death of B35% of cells (Figure 3c). By
contrast, following the same co-treatment, the main popula-
tion of dying MCF-7 cells was AnnV PIþ suggestive of cell
necrosis (Figure 3d). This latter finding was expected as the
MCF-7 cell line is deficient in caspase-3, and thus, apoptotic
cell death is compromised.29 Taken together, these findings
suggest that the co-treatment of different tumor cells with
TAT-NBI1 and erlotinib induces distinct cell-death programs
depending on the genetic background.
Nevertheless, the molecular mechanism that mediates cell-
cycle inhibition by CDK inhibitors, inhibition of the EGFR
pathway and induction of apoptosis remains unclear. We
selected the MDA-MB-468 cell line to further study the
molecular mechanism underlying these events. A feature of
this cell line is an allelic loss of the BRAC1 (breast cancer 1)
gene, which in turn is associated with a poor therapeutic
prognosis. This gene is part of a genome surveillance
complex that senses abnormal DNA structures, such as
double-strand breaks and base pair mismatches.30 As CDK2
is thought to have an important role in the DNA repair
machinery,31 we therefore reasoned that the re-sensitization
of the MDA-MB-468 cell line to erlotinib, that was induced by
CDK2/cyclin A inhibition, may be related to the irreversible
accumulation of non-repaired DNA damage, which in turn
initiates the apoptotic program. DNA damage induces the
phosphorylation of histone 2A.x (H2A.x) at Ser139 by PI3-K-
like kinases, including ATM, ATR and DNA-PKc.32,33 In
addition, the DNA damage effector checkpoint kinase 1
(Chk1) is activated by ATR-dependent phosphorylation to
transduce damage signals to downstream effectors that
control DNA repair and apoptosis.34 Reduced phosphoryla-
tion of Chk1 would dampen its activity and abrogate DNA
damage-induced repair mechanisms, favoring cell apoptosis.
Wemonitored the Ser139 phosphorylation of H2A.x (g-H2A.x)
0
50
100
Ce
ll 
pe
rc
en
ta
ge
0
50
100
Erl
TAT-NBI1
RC
-
-
-
-
5
-
5
-
-
-
-
5
5
5
-
5
-
5
-
-
-
-
2
-
2
-
-
-
-
2
2
2
-
2
-
2
-
-
-
-
2
-
-
-
1
5
-
-
5
2
-
5
-
1
Ce
ll 
pe
rc
en
ta
ge
Erl
RC
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
-
-
-
-
2
-
1
-
-
-
-
2
1
2
-
1
-
2
SubG1 G1 S G2/M
SubG1 G1 S G2/M
SKBr3
A549
24 h
72 h
72 h
TAT-NBI1
48h
MCF-7
MDA-MB-468
Figure 2 TAT-NBI1/erlotinib and roscovitine/erlotinib combination treatments
induce subG1 accumulation in different cell lines. The cell-cycle distribution was
analyzed by flow cytometry following treatment for the periods indicated with
sublethal concentrations of erlotinib (Erl), TAT-NBI1, roscovitine (RC) and
combinations thereof. The doses are expressed in mM in the x axes. The results
obtained after 24, 48 and 72 h of treatment are plotted in panels (a) and (b) for
MDA-MB-468 and SKBr3 cells, respectively. The cell-cycle distribution of (c) A549
and (d) MCF-7 cells after 72 h of treatment is plotted. The data are expressed as the
mean±S.E. (n¼ 3)
0
50
100
0
50
100
0
50
100
0
50
100
Ce
ll 
pe
rc
en
ta
ge
Erl -
-
-
5
5
-
5
5
-
-
-
2
2
-
2
2
-
-
-
2
1
-
1
2
Erl -
-
-
2
5
-
5
2
Ce
ll 
pe
rc
en
ta
ge
TAT-NBI1
TAT-NBI1
AnnV-/PI-AnnV+/PI-AnnV+/PI+AnnV-/PI+
AnnV-/PI-AnnV+/PI-AnnV+/PI+AnnV-/PI+
MDA-MB-468 SKBr3
MCF-7A549
Figure 3 The cell-death mechanism induced by TAT-NBI1/erlotinib co-
treatment differs between the different cell lines analyzed. Cells were treated with
the indicated concentrations (mM) of erlotinib (Erl), TAT-NBI1 or the combination of
both. After 72 h of treatment, apoptotic parameters were analyzed in cells by
cytofluorometry. Quantitative data for AnnexinV/propidium iodide (AnnV/PI) staining
of (a) MDA-MB-468, (b) SKBr3, (c) A549 and (d) MCF-7 cells are shown. The data
are expressed as the mean±S.E. (n¼ 3)
Caspase 8 sensitizing erlotinib resistances
M Orza´ez et al
4
Cell Death and Disease
and the Ser317 phosphorylation of Chk1 (P-Chk1) (Figure 4).
TAT-NBI1/erlotinib co-treatment significantly increased at
48 h the level of g-H2A.x (Figures 4a and b), whereas
decreasing that of P-Chk1 (Figure 4a) in comparison to that
detected following treatment with either compound alone.
Together, these findings indicate that TAT-NBI1/erlotinib co-
treatment that induces the accumulation of DNA defects
(reflected by the increase of g-H2A.x—Figures 4a and b)
might be due to the repression of DNA repair programs
(decreased levels of P-Chk1—Figure 4a) inducing apoptosis.
Analysis of the cell-death pathway induced by TAT-
NBI1/erlotinib co-treatment in erlotinib-resistant MDA-
MB-468 cells. The apoptotic pathway is under the control of
proteins of the Bcl-2 family and of the IAPs.35–37 In particular,
cellular IAP1 (cIAP1) and human X chromosome-encoded
IAP (XIAP) are both implicated in regulation of apoptosis.38
To investigate the role of Bcl-2 family members and IAPs in
the apoptosis induced by TAT-NBI1/erlotinib co-treatment,
we analyzed the expression of Mcl-1, Bcl-xL, XIAP, cIAP1,
Bid, Bax and Bim, when compared with single drug
treatments (Figure 5 and Supplementary Figure S2E). Co-
treatment downregulated the expression of Mcl-1 and Bcl-xL
(Figure 5a), as well as triggering XIAP and cIAP1 depletion
(Figure 5a), whereas it had no effect on the pro-apoptotic Bax
protein (Supplementary Figure S2E).
Two distinct cell-death mechanisms have been linked to
cIAP1 and XIAP depletion, one related to the tumor necrosis
factor-mediated activation of complex-IIB39,40 and the second
involving the ‘genotoxic stress’-mediated assembly of a
recently described complex known as the ‘ripoptosome’.41,42
When we analyzed the pathways by which TAT-NBI1/erlotinib
co-treatment induced cell death, caspase-8 was found
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activated and processed to its active form (Figure 5b), which in
turn cleaved the BH3-only protein Bid, as revealed by a
decrease in the full-length Bid (Figure 5a). In addition, these
events induced the processing of executioner caspase-3 to its
active p20 and p17 subunits (Figure 5b). The BH3-only protein
Bim has been implicated in erlotinib-induced apoptosis,43 and
we found that Bim was upregulated in response to both
erlotinib alone and TAT-NBI1/erlotinib co-treatment
(Supplementary Figure S2E). However, while the latter
induced the accumulation of DNA defects and cell
death, erlotinib alone did not provoke cell death in these
erlotinib-resistant cells (Figures 1 and 3). We next investi-
gated the effect of co-treatment on the initiator caspases -2, -9
and -10. Caspases-2 and  10 were processed to their active
subunits following co-treatment, whereas caspase-9 proces-
sing was not detected (Figure 5b). There was a similar level of
caspase activity induced by co-treatment to that induced by
the apoptosis-inducer doxorubicin (Figure 5c). However,
while doxorubicin-induced apoptosis occurred via the mito-
chondrial-mediated intrinsic pathway characterized by Cyt c
release to the cytoplasm, the liberation of Cyt c induced by
TAT-NBI1/erlotinib co-treatment was minimal (Figure 5d).
These results suggest that TAT-NBI1/erlotinib-induced DNA
damage induces apoptosis through the activation of cas-
pases-2, -8 and -10, independent of the mitochondrial
pathway. We next investigated the role of caspase-2 and
the initiator caspases-8 and -10 in TAT-NBI1/erlotinib-induced
apoptosis. We tested the effect of caspase-2, -8 and -10 loss
on the apoptotic response, as determined by the NBI1/
erlotinib-induced activation of caspase activity in cellular
extracts. The caspase activity (Figure 6a) induced by
co-treatment was not affected by silencing caspase-2
expression and caspases-8 and -10 were processed to their
active subunits (Figure 6b). Knockdown of PIDD also failed to
suppress TAT-NBI1/erlotinib-induced cell death, excluding
the involvement of the PIDDosome as the complex in charge
of apoptosis activation (Figures 6c and d). However, we noted
a marked decrease in caspase activity and cell viability when
caspase-8 (Figure 6e and Supplementary Figure S2D) and
caspase-10 (Figure 6g) were silenced individually. Silencing
caspase-10 prevented processing of caspase-2, whereas
caspase-8 was processed to its active subunits (Figure 6h),
and silencing of caspase-8 did not prevent the processing
of caspases-10 and -2 (Figure 6f). The activation of both
caspases-8 and -10 is needed for full general activation of
caspases as demonstrated in Figures 6e and g. These results
suggest that in MDA-MB-468 cells, the TAT-NBI1/erlotinib co-
treatment induces caspase-2 activation mediated by cas-
pase-10 (Figure 6h) but caspase-2 has not a direct implication
in apoptosis induction (Figure 6a). Similar results have been
previously reported on the still enigmatic activation of
caspase-2 that resulted in cell death in particular cell types,
while in other cells leads to growth suppression coupled to
sensitization to apoptosis.44 Furthermore, we obtain the same
relevant role for caspase-8 in cell sensitazion when the
analysis of the molecular mechanism was performed in the
lung cancer A549 cell line (Supplementary Figure S3).
Despite caspases activation, we found that TAT-NBI1/
erlotinib-dependent cell-death induction was not inhibited by
the caspase inhibitor zVAD-fmk (Z-Val-Ala-Asp(OMe)-fluor-
omethylketone; Supplementary Figure S2C). However, cell
death induced by RC/erlotinib was inhibited by zVAD-fmk.
The molecular basis of these differences could be justified by
the different mechanism of action of the two different CDK/
cyclin inhibitors. Therefore, the kinase selectivity and the
sensitivity of the different CDK/cyclin complexes are different
for the two drugs (Supplementary Table S1 and Bach et al.45).
Hence, such differences could determine the differential
response in the presence of zVAD-fmk.
It has been recently reported that ‘ripoptosome’-mediated
cell death is not inhibited by zVAD-fmk due to the
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Figure 6 Caspases-8 and -10, but not caspase-2, are required to engage the
TAT-NBI1/erlotinib co-treatment-induced apoptotic program. (a) MDA-MB-468 cells
were untreated or transfected with a control (random) or a caspase-2 specific (casp-2)
si-RNA. Silencing of caspase-2 (see Materials and Methods) does not affect NBI1/
erlotinib (at the mM concentrations indicated) co-treatment-induced caspase-3/7
activation evaluated at 48 h post-treatment. (b) Cellular extracts of MDA-MB-468
cells treated as in a, were analyzed by western blot for the expression of caspase-2
to corroborate the silencing as well as for the activation of caspases-8 and -10.
Similar procedures were used for the analyses of the silencing of PIDD (c and d)
and for caspase-8 (e and f) and caspase-10 (g and h; see Materials and Methods)
that inhibited NBI1/erlotinib co-treatment induced caspase-3/7 activity
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ripoptosome’s ability to switch between apoptosis and
necroptosis.41,42 The ‘ripoptosome’ is a cell-death-inducing
platform containing the death domain kinase RIP1, the Fas-
associated death domain protein, caspase-8 and caspase-10
that assembles in response to loss of cIAPs and XIAP.41,42
We next evaluated the influence of the ‘ripoptosome’ in TAT-
NBI1/erlotinib-induced apoptosis. To this end, we use the
RIP1 inhibitor necrostatin-1 (nec-1).46We initially explored the
role of nec-1 as inhibitor of the ‘ripoptosome’ in a cell line
(MDA-MB-231—experimentally determined IC50 values for
this cell line: 420 and 18 mM for erlotinib and TAT-NBI1,
respectively) where such platform was previously character-
ized.42 This cell line respond to etoposide-induced genotoxic
stress through ‘ripoptosome’-mediated and caspase-depen-
dent cell death, which is inhibited by nec-1 (Figure 7a).
Interestingly, nec-1 also inhibited TAT-NBI1/erlotinib-induced
caspase activation in both MDA-MB-231 and MDA-MB-468
cells (Figures 7a and b, respectively). These results suggest
that the ‘ripoptosome’ could have a role in the cell death
induced by TAT-NBI1/erlotinib co-treatment.
Discussion
Recent findings have demonstrated that cancers respond to
therapies targeting receptor TKs. However, the benefits of this
approach are limited by the development of resistances and
the toxic secondary effects induced by high doses of TK
inhibitors, prompting the search for possible alternatives.
Combination therapies have attracted considerable attention
as tools to effectively circumvent the toxicity and resistance
seen with single-agent therapies, even though the underlying
molecular mechanisms remain unclear and the most appro-
priate compounds with which to prime the cell to promote a
synergistic effect remain poorly understood.47 A better
understanding of the synergism and/or potentiation evoked
at the molecular level by drug combinations will aid the
development of improved combinations and personalized
treatments in the future.
Here, we show that co-administration of TAT-NBI1, an ATP
non-competitive inhibitor of the CDK2/cyclin A complex, with
erlotinib, an inhibitor of the TK activity of the EGFR, decreases
the lethal dose of erlotinib in erlotinib-sensitive cells and
sensitizes erlotinib-resistant cells to the cell death provoked
by this drug. TAT-NBI1/erlotinib co-treatment induced necro-
sis in erlotinib-resistant MCF-7 (human breast adenocarci-
noma) cell line that carries different mutations favoring
necrotic cell death over apoptosis.29 By contrast, in the
erlotinib-sensitive SKBr3 (human breast adenocarcinoma)
cell line and the erlotinib-resistant MDA-MB-468 (human
breast adenocarcinoma) and A549 (human alveolar basal
epithelial adenocarcinoma) cell lines, TAT-NBI1/erlotinib co-
treatment induced apoptosis. Remarkably, the lethal dose of
erlotinib in SKBr3 cells was twofold lower in the presence of
TAT-NBI1. This sensitization of both erlotinib-sensitive and
erlotinib-resistant cancer cells demonstrated an important
enhancement in the therapeutic value of EGFR inhibitors
when administrated in combination with ATP non-competitive
CDK-2/cyclin A inhibitors, such as TAT-NBI1.We investigated
themolecularmechanism inMDA-MB-468 andA549 cells and
found that TAT-NBI1/erlotinib co-treatment induced genotoxic
stress as manifested by the accumulation of DNA defects in
treated cells. Indeed, we observed depletion of IAPs and
alterations in the levels of apoptosis-related proteins such as
Bcl-xL, Mcl-1, Bid and Bim together with the activation of the
apoptotic signaling pathway that ultimately activates cas-
pases. Our data suggest that the TAT-NBI1/erlotinib-induced
genotoxic stress could induce the activation of the ‘ripopto-
some,41,42 as the molecular machinery driving the activation
of the initiator caspases-8 and -10. We found that, despite the
reduction of antiapoptotic Bcl-2 protein levels that could
sensitize cells for death programs, TAT-NBI1/erlotinib-
induced caspase-dependent cell death occurred without
activation of the intrinsic apoptotic pathway, as witnessed by
the low levels of Cyt c release and the absence of caspase-9
activation. In the presence of the RIP1 inhibitor nec-1, TAT-
NBI1/erlotinib-induced cell death was drastically impaired.
Moreover, the RNA-mediated silencing of caspase-8, or
caspase-10 but not caspase-2, decreased the TAT-NBI1/
erlotinib-induced activation of effector caspases, implicating a
signaling pathway in which caspase-2 is positioned down-
stream of caspase-8/10 (Figure 7c). Interestingly, it has been
recently reported that a time-staggered treatment with
erlotinib sensitizes a subset of breast cancer cells to a DNA
damaging agent as doxorubicin and the process is mediated
by caspase-8 activation.47 The molecular mechanism in
charge of caspase-8 activation has not been reported
although it is tempting to speculate that it could be related to
the one described in the present study.
Materials and Methods
Antibodies, chemicals and cell lines. Antibodies for Bax (No.2772),
Bcl-xL (No.2764), Bid (No.2002), Bim (No.2819), caspase-3 (No.9662), caspase-8
(No.9748), caspase-9 (No.9508), phospho-Chk1 (No.23425), GAPDH (No.2018),
g-H2Ax (Ser 139; No.9718S), cIAP1 (No.4952), Mcl-1 (No.4572) and XIAP (No.2042)
were from Cell Signaling (Danvers, MA, USA). PIDD antibody (ALX-804–837) was
from Enzo Life Sciences (Farmingdale, NY, USA). Caspase-10 antibody (M059–3)
was purchased from MBL (Woburn, MA, USA) and caspase-2 antibody (MAB3507)
from Millipore (Billerica, MA, USA). Erlotinib was initially provided as gift from
Genentech (San Francisco, CA, USA) and later acquired from LC Laboratories
(Woburn, MA, USA). TAT-NBI1 was synthesized as described previously22 and
it is also available from Calbiochem (Darmstadt, Germany); RC and etoposide
were from Sigma (Munich, Germany) and necrostatin-1 from Enzo Life Sciences.
The MDA-MB-468, SKBr3, MCF-7, A549, Jurkat, HL60 and Saos-2 cell lines
were purchased from ATCC (Barcelona, Spain). Cell media (Leibovitz’s l-15,
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Figure 7 Engagement of co-treatment-induced apoptotic program depends
on the ripoptosome. (a) Etoposide (25 mM) induced activation of caspase-3/7 in
MDA-MB-231 cells was inhibited in the presence of nec-1 (100mM). Similarly, the
caspase-3/7 activation induced by the NBI1/erlotinib co-treatment (at the mM
concentrations indicated) in these cells was inhibited by nec-1. (b) The NBI1/
erlotinib (at the mM concentrations indicated) co-treatment-induced caspase-3/7
activation in MDA-MB-468 cells was inhibited by nec-1.
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DMEM, McCoys 5A, F12, RPMI) and fetal bovine serum was purchased for the
different cell lines from GIBCO BRL Life Technologies (Paisley, UK).
Cell cultures. A549, MCF-7 and Saos-2 cell lines were grown in DMEM, the
SKBr3 cell line was grown in McCoy’s and the HL-60 and Jurkat cell lines were
grown in RPMI. All these media were supplemented with 10% fetal bovine serum
and the cultures were maintained at 37 1C under a 5% CO2 atmosphere. The
MDA-MB-468 and MDA-MB-231 cell lines were grown as a monolayer in
Leibovitz’s l-15 medium supplemented with 10% fetal bovine serum at 37 1C
without CO2.
MTT and trypan blue cell viability assays. Mitochondrial activity was
measured using a MTT colorimetric assay. Cells were grown in 96-well plates at a
cell density of 12500 cells/well for the MDA-MB-468 line and 5000 cells/well for the
MCF-7 and SKBr3 cell lines. The HL60, Jurkat and Saos-2 cell lines were seeded
at 3000, 5000 and 10 000 cells per well, respectively. The density for A549 was
2000 cells/well. After seeding, the cells were left to adhere to the plate overnight,
they were then treated with the compounds of interest incubated at 37 1C. Four
hours before the end of the treatment 20ml/well of MTT (5 mg/ml in PBS) was
added to each well and the plates were incubated for a further 4 hours at 37 1C.
Finally, the medium was removed and the precipitated formazan crystals were
dissolved in optical grade DMSO (100ml). The plates were read at 570 nm on a
Wallac 1420 workstation, PerkinElmer Life Sciences (San Francisco, CA, USA).
For IC50 determination, the cells were treated with seven different concentrations
of the drugs and the cell viability determined by MTT. Data for three independent
experiments were adjusted to variable slope sigmoidal dose–response curves, and
the IC50 was determined using the Graph Pad 3.0 software. For trypan blue cell
viability assays, cell suspensions were stained with trypan blue 0.004% (1 : 1), and
cells were counted using an hemocytometer from Sigma. Cell death percentage
was calculated from the ratio of positive-stained cells to total number of cells.
Determination of apoptosis by AnnexinV/PI staining. To estimate
the number of apoptotic cells, cells were seeded as indicated above, and they
were labeled with Alexa fluoresceinisothiocyanate-conjugated Annexin V (BD
Bioscience, San Jose, CA, USA) together with PI dead cell counterstain, according
to the manufacturer’s recommendations.
Cell-cycle analysis. For cell-cycle analyses, MDA-MB-468 cells were
seeded at 125 000 cells/ml, MCF-7 and SKBr3 were seeded at 65 000 cells/ml
and A549 at 25 000 cells/ml. After treatments, the cells were fixed in 80% ice-cold
ethanol and labeled with PI (50 mg/ml) in the presence of 500mg/ml RNAase.
Cytofluorometric determinations were performed with a Cytomics FC 500 from
Beckman Coulter (Barcelona, Spain).
Immunofluorescence detection of clustered c-H2AX foci. MDA-
MB-468 cells were seeded on coverslips at a density of 125 000 cells/ml. After
treatments, the cells were fixed in 4% formaldehyde/PBS for 15 min,
permeabilized with 0.3% Triton X-100/PBS for 15 min and blocked with 0.2%
gelatin/PBS for 1 h. After overnight incubation at 4 1C with the g-H2Ax primary
antibody, the cells were labeled for 2 h with the Alexa Fluor 555 F(ab)2 fragment
goat anti-Rabbit secondary antibody at room temperature. Coverslips were
mounted using Vectashield mounting medium with DAPI and foci were visualized
on a Leica DM 6000 microscope (Leica DC500 camera) with a  40 objective
(Weztlar, Germany).
Gene silencing with small interfering RNA. The siRNA for the human
caspase-10 mRNA target sequence (No.6357) and the negative control siRNA
(No.6568) were purchased from Cell Signaling. The siRNAs for caspase-2 and -8
(No.835:CASP-2 and No.841:CASP8, respectively) were purchased from Thermo
Scientific (Walthman, MA, USA). The siRNA sequence for PIDD was provided by
Dr. Tencho Tenev42 and purchased from Qiagen (Hilden, Germany). The siRNA
oligonucleotides were transfected in Optimem at the recommended concentrations
using Lipofectamine 2000 (Invitrogen, Paisley, UK), according to the manufacturer’s
instructions. At 48 h post-transfection, the cells were treated with the compounds
of interest at the concentrations indicated.
Caspase activation assays in cellular models (caspase activity).
To analyze caspase activation, MDA-MB-468 cells were seeded at 125 000 cells/
ml and A549 at 50 000 cells/ml, and after 48 h in the presence of the compounds
of interest at the concentrations indicated, caspase activity was measured as
described previously in Mondragon et al.48
Cyt c release from mitochondria. To quantify the release of Cyt c from
mitochondria, MDA-MB-468 cells were seeded at 125 000 cell/ml, and after 48 h in
the presence of the compounds of interest at the concentrations indicated, the
InnocyteTM Flow Cytometric Cytochrome c Release kit (Calbiochem) was used
according to the manufacturer’s recommendations. The cells were analyzed on a
Cytomics FC 500 (Beckman Coulter) flow cytometer.
Immunoblotting. Whole-cell extracts were obtained by lysing cells in a buffer
containing 25 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% SDS plus
protease and phosphatase inhibitors. The protein concentration was determined
by the BCA protein assay. Cell lysates were resolved by SDS-PAGE, transferred
to nitrocellulose membranes and immunoblotted following standard procedures.
Evaluation of erlotinib, RC and TAT-NBI1 sublethal concentra-
tions. To determine such concentrations for the different cell lines, we defined
as sublethal those concentrations that induced a percentage of cell deatho10%
in MTT assays (Supplementary Table SII).
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